MIRA INFORM REPORT

 

 

Report No. :

333391

Report Date :

27.07.2015

 

IDENTIFICATION DETAILS

 

Name :

SANOFI-SYNTHELABO (INDIA) PRIVATE LIMITED (w.e.f. 28.05.2015)

 

 

Formerly Known As :

SANOFI-SYNTHELABO (INDIA) LIMITED

 

 

Registered Office :

Sanofi House, CTS No.117-B, L and T Business Park, Saki Vihar Road, Powai, Mumbai – 400072, Maharashtra

Tel. No.:

91-22-28278000

 

 

Country :

India

 

 

Financials (as on) :

31.03.2014

 

 

Date of Incorporation :

25.10.2002

 

 

Com. Reg. No.:

11-137682

 

 

Capital Investment / Paid-up Capital :

Rs.280.000 Million

 

 

CIN No.:

[Company Identification No.]

U24230MH2002PTC137682

 

 

IEC No.:

0896006824

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMS35209G

 

 

PAN No.:

[Permanent Account No.]

AACCS1421J

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturing and trading of Pharmaceutical Products.

 

 

No. of Employees :

Not Available

 

 

RATING & COMMENTS

 

MIRA’s Rating :

A (58)

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Maximum Credit Limit :

USD 7200000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a subsidiary of “Sanofi S.A”

 

It is an established company incorporated during the year 2002 having a good track record.

 

Profit of the company has sharply declined during FY 2014. However, general financial position of the company is sound.

 

Fundamentals of the company are strong and healthy.

 

Further the rating also takes into consideration debt free balance sheet of the company and support received to the subject from its holding company.

 

Trade relations are reported as fair. Business is active. Payment terms are reported to be regular and as per commitment.

 

In view of strong holding support and sound financial base, the company can be considered good for normal business dealings at usual trade terms and conditions.

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31, 2015

 

Country Name

Previous Rating

(31.12.2014)

Current Rating

(31.03.2015)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

EXTERNAL AGENCY RATING

 

Not Available

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2013.

 

 

 

 

LOCATIONS

 

Registered Office :

Sanofi House, CTS No.117-B, L and T Business Park, Saki Vihar Road, Powai, Mumbai – 400072, Maharashtra, India

Tel. No.:

91-22-28278000

Fax No.:

91-22-28370939

E-Mail :

christophe.germain@sanogi-aventis.com

info@sanofi-synthelabo.com

shailesh_ayyangar@sanofi.aventls.com

Website :

www.sanofi-synthelabo.com

 

 

Factory 1 :

Village 7 P.O. Indrad, Taluka Kadi, District Mehsana, Gujarat, India

 

 

DIRECTORS

 

AS ON 26.09.2014

 

Name :

Shailesh Ayyangar

Designation :

Managing Director

Address :

3 A / 3 B, Benreeza Apartment, 24 Khan Abdul Gaffar Khan Road, Worli, Mumbai – 400025, Maharashtra, India

Date of Birth/Age :

15.10.1954

Date of Appointment :

18.11.2010

DIN No.:

00268076

 

 

Name :

Virginie Simone Jeanine Verrechia

Designation :

Director

Address :

Shimara 11/ 12/ 13 East 18th Road, Khar West, Mumbai – 400052, Maharashtra, India

Date of Birth/Age :

18.10.1969

Date of Appointment :

01.07.2012

DIN No.:

05302127

 

 

Name :

Antoine Rene Jacque Ortoli

Designation :

Director

Address :

62, Chemin Des Hauts Degrisy 78860 Saint Nomla Breteche, France

Date of Birth/Age :

25.05.1953

Date of Appointment :

14.04.2011

DIN No.:

03472962

 

 

Name :

Francois Jean Louis Briens

Designation :

Director

Address :

11, Rue Simonet, Paris – 75013, France

Date of Birth/Age :

20.05.1959

Date of Appointment :

08.04.2011

DIN No.:

03472959

 

MAJOR SHAREHOLDERS

 

AS ON 26.09.2014

 

Names of Shareholders

 

 

No. of Shares

Sanofi

 

27999994

Ayyangar Shailesh

 

1

Ortoli Antoine

 

1

Sanofi Aventis Participations

 

1

Secipe

 

1

Sanofi Development Pharma

 

1

SPI

 

1

 

 

 

Total

 

28000000

 

Equity Share Break up (Percentage of Total Equity)

 

AS ON 26.09.2014

 

Category

Percentage

Foreign holdings [Foreign institutional investor(s), Foreign companie(s) Foreign financial institution(s), Non-resident Indian(s) or Overseas Corporate bodies or Others]

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturing and trading of Pharmaceutical Products.

 

 

Products :

Item Code No. (ITC Code)

 

Product Description

300490.81

Sodium Valporate

300490.11

Aminodarone (Cordarone)

300490.99

Clopidogrel (Plavix)

300490.11

Low Molecule Weight Heparine

Thrombosis

Plavix (clopidogrel bisulfate)

 

Cardiovascular

http://www.sanofi-aventis.in/live/Wskins/mcl2005/images/pixel.gifCordarone (amiodarone hydrochloride)  

Adenocor IV (adenosine)  

Primacor IV (milrinone lactate)  

 

Central Nervous System

http://www.sanofi-aventis.in/live/Wskins/mcl2005/images/pixel.gifValparin (sodium valproate + Valproic acid)  

Depakote (divalproex Sodium)  

Aedon (clobazam)

Stilnoct (zolpidem tartrate)  

 

Internal Medicine

http://www.sanofi-aventis.in/live/Wskins/mcl2005/images/pixel.gifMyoril (thiocolchicoside)  

 

 

Brand Names :

Not Available

 

 

Agencies Held :

Not Available

 

 

Exports :

Not Available

 

 

Imports :

Not Available

 

 

Terms :

Not Available

 

PRODUCTION STATUS – NOT AVAILABLE

 

 

GENERAL INFORMATION

 

Suppliers :

Company Name :

Not Available

Name of the Person :

Not Available

Contact No.:

Not Available

Since How Long Known :

Not Available

Maximum Limit Dealt :

Not Available

Experience :

Not Available

Remark :

Not Available

 

 

Customers :

Company Name :

Not Available

Name of the Person :

Not Available

Contact No.:

Not Available

Since How Long Known :

Not Available

Maximum Limit Dealt :

Not Available

Experience :

Not Available

Remark :

Not Available

 

 

No. of Employees :

Not Available

 

 

Bankers :

Banker Name :

BNP Paribas

Branch :

Sakar – II, Ellisbridge, Ahmedabad, Gujarat, India

Person Name (With Designation) :

Not Available

Contact Number :

Not Available

Name of Account Holder :

Not Available

Account Number :

Not Available

Account Since (Date/Year of Account Opening) :

Not Available

Average Balance Maintained :

Not Available

Credit Facilities Enjoyed (CC/OD/Term Loan) :

Not Available

Account Operation :

Not Available

Remark :

Not Available

 

 

Auditors :

 

Name :

S. R. Batliboi and Company

Chartered Accountants

Address :

14th Floor, The Ruby, Senapati Bapat Marg, Dadar-West, Mumbai – 400028, Maharashtra, India

PAN No.:

AALFS0506L

 

 

Memberships :

Not Divulged

 

 

Collaborators :

Not Divulged

 

 

Holding Company :

  • Sanofi S.A.

 

 

Fellow Subsidiaries :

  • Genzyme Corporation
  • Sanofi-Aventis Deutschland GmbH
  • Genzyme India Private Limited
  • Sanofi-Aventis Groupe S.A., France
  • Merial Hub UK
  • Sanofi-Aventis Gulf FZE LLC
  • Sanofi Chimie S.A
  • Sanofi-Aventis Hong Kong Limited
  • Sanofi India Limited
  • Sanofi-Aventis kazakhstan LLP
  • sanofi KK
  • Sanofi-aventis Korea Co. Limited
  • Sanofi Pasteur Inc.
  • Sanofi-Aventis Lanka Limited
  • Sanofi Pasteur India Private Limited
  • sanofi-aventis Pakistan Limited
  • Sanofi Pasteur S.A., France
  • Sanofi-Aventis Singapore Pte. Limited
  • Sanofi Winthrop Industrie S.A., France
  • Sanofi-Aventis Taiwan Co Limited
  • Sanofi-aventis (Malaysia) SDN BHD
  • Sanofi-Aventis US Inc.
  • Sanofi-Aventis (Thailand) Limited
  • Shantha Biotechnics Limited
  • Sanofi-aventis de Chile S.A.
  • Sanofi-Aventis Spa

 

 

CAPITAL STRUCTURE

 

AS ON 26.09.2014

 

Authorised Capital:

No. of Shares

Type

Value

Amount

 

 

 

 

28000000

Equity Shares

Rs.10/- each

Rs.280.000 Million

 

 

 

 

 

Issued, Subscribed & Paid-up Capital:

No. of Shares

Type

Value

Amount

 

 

 

 

28000000

Equity Shares

Rs.10/- each

Rs.280.000 Million

 

 

 

 

 


 

FINANCIAL DATA

[all figures are in Rupees Million]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2014

31.03.2013

31.03.2012

I.              EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

280.000

280.000

280.000

(b) Reserves & Surplus

2252.300

2206.500

1568.500

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

2532.300

2486.500

1848.500

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

0.000

0.000

0.000

(b) Deferred tax liabilities (Net)

0.000

0.000

0.000

(c) Other long term liabilities

0.000

0.000

0.000

(d) long-term provisions

91.400

62.800

51.100

Total Non-current Liabilities (3)

91.400

62.800

51.100

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

0.000

0.000

0.000

(b) Trade payables

393.900

370.900

196.900

(c) Other current liabilities

138.500

71.800

52.900

(d) Short-term provisions

62.100

40.600

32.300

Total Current Liabilities (4)

594.500

483.300

282.100

 

 

 

 

TOTAL

3218.200

3032.600

2181.700

 

 

 

 

II.            ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

401.800

4.257

467.900

(ii) Intangible Assets

1365.900

0.004

1.000

(iii) Capital work-in-progress

3.900

0.000

0.000

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.000

0.000

0.000

(c) Deferred tax assets (net)

5.500

0.150

6.500

(d)  Long-term Loan and Advances

136.400

1.017

672.900

(e) Other Non-current assets

0.000

0.000

0.000

Total Non-Current Assets

1913.500

5.428

1148.300

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

560.800

3.282

259.600

(c) Trade receivables

445.600

2.626

171.200

(d) Cash and cash equivalents

245.000

18.472

284.100

(e) Short-term loans and advances

42.500

0.406

301.800

(f) Other current assets

10.800

0.112

16.700

Total Current Assets

1304.700

24.898

1033.400

 

 

 

 

TOTAL

3218.200

3032.600

2181.700

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

 

31.03.2014

31.03.2013

31.03.2012

 

SALES

 

 

 

 

 

Income

3554.400

3265.700

2431.100

 

 

Other Income

47.200

148.300

91.400

 

 

TOTAL                                              (A)

3601.600

3414.000

2522.500

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Materials Consumed

546.800

379.500

334.800

 

 

Purchase of Stock-in-trade

718.600

380.800

274.800

 

 

Changes in Inventories of finished goods, work-in-progress and stock-in-trade

(183.900)

(53.300)

17.900

 

 

Employee Benefits Expenses

437.800

296.500

138.000

 

 

Other Expenses

1674.900

1403.000

955.500

 

 

TOTAL                                              (B)

3194.200

2406.500

1721.000

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)     (C)

407.400

1007.500

801.500

 

 

 

 

 

Less

FINANCIAL EXPENSES                                    (D)

0.100

0.000

0.300

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                (E)

407.300

1007.500

801.200

 

 

 

 

 

Less

DEPRECIATION/ AMORTISATION                     (F)

337.900

65.000

65.100

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX (E-F)                  (G)     

69.400

942.500

736.100

 

 

 

 

 

Less

TAX                                                                  (H)

23.600

304.500

238.500

 

 

 

 

 

 

PROFIT/(LOSS) AFTER TAX (G-H)                    (I)

45.800

638.000

497.600

 

 

 

 

 

 

Earnings Per Share (Rs.)

1.64

23.00

17.77

 

CURRENT MATURITIES OF LONG TERM DEBT DETAILS

 

 

Particulars

 

31.03.2014

31.03.2013

31.03.2012

Current Maturities of Long term debt

NA

NA

NA

Cash generated from operations

NA

NA

NA

Net cash flow from (used in) operations

340.500

986.500

828.900

 

 

KEY RATIOS

 

 

PARTICULARS

 

 

31.03.2014

31.03.2013

31.03.2012

Net Profit Margin

PAT / Sales

(%)

1.29

19.54

20.47

 

 

 

 

 

Operating Profit Margin

(PBDIT/Sales)

(%)

11.46

30.85

32.97

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets)

(%)

2.16

3123.34

33.84

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.03

0.38

0.40

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.00

0.00

0.00

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

2.19

0.05

3.66

 


 

FINANCIAL ANALYSIS

[all figures are in Rupees Million]

 

DEBT EQUITY RATIO

 

Particular

31.03.2012

31.03.2013

31.03.2014

 

Rs. In Million

Rs. In Million

Rs. In Million

Share Capital

280.000

280.000

280.000

Reserves & Surplus

1568.500

2206.500

2252.300

Net worth

1848.500

2486.500

2532.300

 

 

 

 

long-term borrowings

0.000

0.000

0.000

Short term borrowings

0.000

0.000

0.000

Total borrowings

0.000

0.000

0.000

Debt/Equity ratio

0.000

0.000

0.000

 

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2012

31.03.2013

31.03.2014

 

Rs. In Million

Rs. In Million

Rs. In Million

Sales

2431.100

3265.700

3554.400

 

 

34.330

8.840

 

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2012

31.03.2013

31.03.2014

 

Rs. In Million

Rs. In Million

Rs. In Million

Sales

2431.100

3265.700

3554.400

Profit

497.600

638.000

45.800

 

20.47%

19.54%

1.29%

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check list by info agents

Available in Report (Yes/No)

1

Year of establishment

Yes

2

Constitution of the entity -Incorporation details

Yes

3

Locality of the entity

Yes

4

Premises details

No

5

Buyer visit details

--

6

Contact numbers

Yes

7

Name of the person contacted

No

8

Designation of contact person

No

9

Promoter’s background

Yes

10

Date of Birth of Proprietor / Partners / Directors

Yes

11

Pan Card No. of Proprietor / Partners

No

12

Voter Id Card No. of Proprietor / Partners

No

13

Type of business

Yes

14

Line of Business

Yes

15

Export/import details (if applicable)

No

16

No. of employees

No

17

Details of sister concerns

Yes

18

Major suppliers

No

19

Major customers

No

20

Banking Details

Yes

21

Banking facility details

No

22

Conduct of the banking account

--

23

Financials, if provided

Yes

24

Capital in the business

Yes

25

Last accounts filed at ROC, if applicable

Yes

26

Turnover of firm for last three years

Yes

27

Reasons for variation <> 20%

--

28

Estimation for coming financial year

No

29

Profitability for last three years

Yes

30

Major shareholders, if available

Yes

31

External Agency Rating, if available

No

32

Litigations that the firm/promoter involved in

--

33

Market information

--

34

Payments terms

No

35

Negative Reporting by Auditors in the Annual Report

No

 

 

NO CHARGES EXIST FOR COMPANY

 

 

FIXED ASSETS:

 

·         Land

·         Building

·         Plant and Machinery

·         Furniture and Fixture

·         Office Equipment

·         Computer

·         Vehicles

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

 

Unit

Indian Rupees

US Dollar

1

Rs.63.89

UK Pound

1

Rs.99.10

Euro

1

Rs.70.12

 

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

NKT

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

6

OPERATING SCALE

1~10

7

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

7

--PROFITABILITY

1~10

6

--LIQUIDITY

1~10

7

--LEVERAGE

1~10

6

--RESERVES

1~10

7

--CREDIT LINES

1~10

6

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

NO

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

 

 

 

TOTAL

 

58

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NB

NEW BUSINESS

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.